Considering that Orai3 expression is inversely associated with the PC patients’ survival time and it is overexpressed in a certain proportion of pancreatic tumors, Orai3 appears to be an attractive therapeutic target, at least in the cases where its expression is elevated. This evidence concerns the gene ORAI3 and pancreatic neoplasm.